...
首页> 外文期刊>Taiwanese journal of obstetrics and gynecology >The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population.
【24h】

The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population.

机译:GPR30与亚洲人群中浸润性乳腺导管癌的主要生物标志物之间的相互作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: G-protein-coupled receptor 30 (GPR30) has been reported to be a novel estrogen receptor alpha (ERalpha) in vitro. Therefore, the interactions among GPR30, ERalpha, progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2eu), and their prognostic utilities in the infiltrating ductal carcinoma (IDC) of the breast were evaluated. MATERIALS AND METHODS: Messenger RNA (mRNA) levels of GPR30, ERalpha, PR and HER-2eu in the tumor samples of 118 Taiwanese IDC patients and 27 non-tumor mammary tissues were measured via quantitative polymerase chain reaction analyses. The correlations of GPR30 mRNA levels with clinical parameters, i.e. tumoron-tumor, ERalpha, PR, HER-2eu, age, lymph node metastasis, lymph-vascular invasion, grade, stage and patient survival, were assessed by using appropriate statistical analyses. RESULTS: GPR30 expression was observed to be lower in IDC (p < 0.001) than in non-tumor mammary tissues. Importantly, GPR30 mRNA level was positively correlatedwith that of ERalpha (p = 0.001) and PR (p = 0.001) but not correlated with that of HER-2eu when they were analyzed as continuous variables. However, lower GPR30 was noticed in tumors with HER-2eu protein overexpression. GPR30 expression was not correlated with age, lymph node metastasis, lymph-vascular invasion, grade and stage in IDC. GPR30 expression was not an independent prognostic factor for patient survival. CONCLUSION: GPR30 expression is downregulated in IDC. GPR30 is preferentially co-expressed with ER and/or PR but is lowly expressed in HER-2eu(+) tumors. The correlation of GPR30 expression with clinical parameters, including patient survival, was not evident in this cohort.
机译:目的:G蛋白偶联受体30(GPR30)在体外是一种新型的雌激素受体α(ERalpha)。因此,评估了GPR30,ERα,孕激素受体(PR)和人表皮生长因子受体2(HER-2 / neu)之间的相互作用,以及它们在乳腺浸润性导管癌(IDC)中的预后作用。材料与方法:通过定量聚合酶链反应分析法测量了118例台湾IDC患者和27个非肿瘤乳腺组织的肿瘤样本中GPR30,ERalpha,PR和HER-2 / neu的信使RNA(mRNA)水平。通过使用适当的方法评估GPR30 mRNA水平与临床参数的相关性,即肿瘤/非肿瘤,ERalpha,PR,HER-2 / neu,年龄,淋巴结转移,淋巴管浸润,等级,分期和患者生存率统计分析。结果:IDC中的GPR30表达低于非肿瘤乳腺组织(p <0.001)。重要的是,当将GPR30 mRNA水平作为连续变量进行分析时,它们与ERalpha(p = 0.001)和PR(p = 0.001)呈正相关,而与HER-2 / neu则不呈正相关。然而,在HER-2 / neu蛋白过表达的肿瘤中发现较低的GPR30。 GPR30的表达与IDC的年龄,淋巴结转移,淋巴管浸润,等级和分期无关。 GPR30表达不是患者生存的独立预后因素。结论:IDC中GPR30表达下调。 GPR30优先与ER和/或PR共表达,但在HER-2 / neu(+)肿瘤中低表达。在该队列中,GPR30表达与临床参数(包括患者生存率)之间的相关性并不明显。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号